Report of the American Animal Hospital Association (AAHA) Canine Vaccine Task Force: Executive Summary and 2003 Canine Vaccine Guidelines and Recommendations

摘要

While the debate over the frequency of vaccine use has dominated both veterinary and pet owner-directed literature recently, few will debate the tremendous benefits that vaccines have brought to both veterinary and human health care. As veterinarians, it is therefore safe to say that no single achievement has had greater impact on the lives and well-being of our patients, our clients, and our ability to prevent infectious diseases than the development and ongoing improvements in companion animal vaccines. The evolution of biologics represents a continuum of advances encompassing efficacy, safety, and usage. Early vaccines did not enjoy the same safety and efficacy profiles of currently available products, often resulting in adverse reactions or short durations of immunity (DOD. The resulting recommendations for revaccination reflected these product limitatiosn, and most of the widely accepted recommendations for revaccination were based on a "better safe than sorry" approach because the diseasesthese vaccines were designed to prevent were widespread and devastating. While the evolution of scientific knowledge has resulted in tremendous improvements in the fiend of vaccinology, the ultimate goal of combining 100 percent efficacy and 100 percentsafety into the same vaccine product is not a reality at this time. Therefore, current knowledge supports the statement that no vaccine is always safe, no vaccine is always protective, and no vaccine is always indicated. However, the information that this statement is based on is in a constant state of flux; hence, the historical and current debate on appropriate vaccine use.